Repare Therapeutics Inc. — Director's Dealing 2021

Aug 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Repare Therapeutics Inc. (RPTX)
CIK: 0001808158
Period of Report: 2021-08-23

Reporting Person: Bonita David P (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-23	Common Stock	S	6885	$34.06	Disposed	3249972	Indirect
2021-08-23	Common Stock	S	209	$34.06	Disposed	98401	Indirect
2021-08-24	Common Stock	S	3920	$34.07	Disposed	3246052	Indirect
2021-08-24	Common Stock	S	119	$34.07	Disposed	98282	Indirect
2021-08-25	Common Stock	S	6874	$34.34	Disposed	3239178	Indirect
2021-08-25	Common Stock	S	208	$34.34	Disposed	98074	Indirect

Footnotes

F1: These shares of the Issuer's common stock were sold in a block order at price of $34.06 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments VII, LP ("OPI VII").

F2: These shares of the Issuer's common stock are held of record by OPI VII. OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. The Reporting Person is a member of OrbiMed Advisors. OrbiMed Advisors and GP VII exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F3: These shares of the Issuer's common stock were sold in a block order at price of $34.06 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Partners Master Fund Limited ("OPM").

F4: These shares of the Issuer's common stock are held of record by OPM. OrbiMed Capital LLC ("OrbiMed Capital") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM.

F5: Each of GP VII, OrbiMed Advisors, OrbiMed Capital, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of GP VII, OrbiMed Advisors, OrbiMed Capital, or the Reporting Person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

F6: These shares of the Issuer's common stock were sold in a block order at price of $34.07 pursuant to a Rule 10b5-1 trading plan established by OPI VII.

F7: These shares of the Issuer's common stock were sold in a block order at price of $34.07 pursuant to a Rule 10b5-1 trading plan established by OPM.

F8: These shares of the Issuer's common stock were sold in a block order at price of $34.34 pursuant to a Rule 10b5-1 trading plan established by OPI VII.

F9: These shares of the Issuer's common stock were sold in a block order at price of $34.34 pursuant to a Rule 10b5-1 trading plan established by OPM.